Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Contineum Therapeutics, Inc. (NASDAQ: CTNM) is now covered by analysts at Jones Trading. They set a "buy" rating and a $23.00 price target on the stock.
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $25.00 price target on the stock.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its price target lowered by analysts at Robert W. Baird from $32.00 to $16.00. They now have an "outperform" rating on the stock.